Evidence map›Paper›PMID 25651921›Full record

ArticleClinical and vaccine immunology : CVI2015

Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies.

S Blumental, J C Moïsi, L Roalfe, M Zancolli, M Johnson, P Burbidge, R Borrow, S Yaro, J E Mueller, B D Gessner and 1 more

Open access · diamondAbstract readComparative Study
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Transcriptomic analysis ofMicrobial genomics · 2025
    Article
  2. Pneumococcal Capsular Polysaccharide Immunity in the Elderly.Clinical and vaccine immunology : CVI · 2017
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

S BlumentalPaediatric Infectious Diseases Unit, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium UCL Institute of Child Health, London, United Kingdom sophie.blumental@ulb.ac.be d.goldblatt@ucl.ac.uk.
J C MoïsiAgence de Médecine Préventive, Paris and Ferney-Voltaire, France.
L RoalfeUCL Institute of Child Health, London, United Kingdom.
M ZancolliUCL Institute of Child Health, London, United Kingdom.
M JohnsonUCL Institute of Child Health, London, United Kingdom.
P BurbidgeUCL Institute of Child Health, London, United Kingdom.
R BorrowPublic Health England Vaccine Evaluation Unit, Manchester, United Kingdom.
S YaroCentre Muraz, Bobo-Dioulasso, Burkina Faso.
J E MuellerEHESP School of Public Health, Paris, France.
B D GessnerAgence de Médecine Préventive, Paris and Ferney-Voltaire, France.
D GoldblattUCL Institute of Child Health, London, United Kingdom sophie.blumental@ulb.ac.be d.goldblatt@ucl.ac.uk.
University College London · GBAgence de Médecine Préventive · FRCentre Muraz · BFÉcole des Hautes Études en Santé Publique · FRPublic Health England · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Streptococcus pneumoniae serotype 1 (Sp1) constitutes an important cause of seasonal endemic meningitis in all age groups in the African meningitis belt. Despite a higher meningitis incidence, the Burkinabé population has an Sp1-specific antibody seroprevalence similar to that reported in the United Kingdom (UK). We aimed to establish whether the opsonophagocytic activity (OPA) of pneumococcal IgG naturally present in Burkina Faso differs from that seen in individuals in the UK and to compare the OPAs generated by natural and vaccine-induced immunity. Samples collected from pneumococcal vaccine-naive Burkinabé and UK subjects were matched for age (1 to 39 years) and anti-Sp1 IgG level, analyzed for OPA to 3 S. pneumoniae serotypes (1, 5, and 19A), and compared to postvaccine samples. Furthermore, the Burkinabé samples were assessed for IgG avidity and serotype-specific IgM concentrations. One hundred sixty-nine matched serum samples from both populations were selected. A greater proportion of Burkinabé subjects aged 1 to 19 years had functional Sp1 activity (OPA ≥ 8) compared to UK subjects (12% versus 2%, P < 0.001); however, the proportions were similar among adults (9%). The correlation between Sp1 IgG concentration and OPA was good (P < 0.001), but many individuals had nonfunctional IgG, which was not related to avidity. While the Sp1 IgM concentrations correlated with OPA, not all of the function in serum samples with low IgG could be attributed to IgM. Finally, vaccine-induced Sp1-specific IgG was more functional than equivalent amounts of naturally occurring IgG. In conclusion, despite a substantially higher pneumococcal meningitis incidence, no decreased functional immunity to Sp1 could be evidenced in the Burkinabé population compared to that in the population from the UK. Furthermore, the naturally induced antibodies were less functional than vaccine-induced antibodies.

Indexed as

SerogroupAdolescentAdultAntibodies, BacterialAntibody AffinityBurkina FasoChildChild, PreschoolCohort StudiesCross-Sectional StudiesFemaleHumansImmunoglobulin GIncidenceInfantMaleAntibodies, BacterialImmunoglobulin GOpsonin Proteins

Identifiers

PMID25651921
PMCPMC4375351
OpenAlexW1990854867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.